小分子TKI联合同期放疗治疗晚期非小细胞肺癌脑转移患者的近期效果观察  

Short-term effects of small-molecule TKI combined with concurrent radiotherapy in the treatment of patients with advanced non-small cell lung cancer with brain metastasis

作　　者：魏亮[1] 王光学[2] 洪暄[3] 杨成[1] 孙志扬[1] 钟春龙[1] 李钦传[3] WEI Liang;WANG Guang-xue;HONG Xuan;YANG Cheng;SUN Zhi-yang;ZHONG Chun-long;LI Qin-chuan(Department of Neurosurgery,Dongfang Hospital Affiliated to Tongji University,Shanghai 200120,China;Center for Translational Medicine,Dongfang Hospital Affiliated to Tongji University,Shanghai 200120,China;Department of Cardiothoracic Surgery,Dongfang Hospital Affiliated to Tongji University,Shanghai 200120,China)

机构地区：[1]同济大学附属东方医院神经外科,上海200120 [2]同济大学附属东方医院转化医学研究中心,上海200120 [3]同济大学附属东方医院心胸外科,上海200120

出　　处：《实用药物与临床》2019年第11期1144-1147,共4页Practical Pharmacy and Clinical Remedies

基　　金：上海市浦东新区卫生系统重点学科群建设资助(PWZxq2017-13)

摘　　要：目的探讨小分子酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI)联合同期放疗治疗晚期非小细胞肺癌脑转移患者的近期效果。方法回顾性分析2017年1月至2019年1月我院71例晚期非小细胞肺癌脑转移患者的临床资料。根据治疗方法分组,以采用全脑放疗治疗的34例患者为对照组,以采用小分子TKI联合同期放疗的37例患者为研究组。比较两组近期效果、生活质量(Quality of life,QOL)评分及不良反应。结果治疗后,研究组脑转移灶疾病控制率(72.97%)高于对照组(47.06%)(P<0.05);研究组QOL评分高于对照组(P<0.05);两组恶心呕吐、腹泻、皮疹、疲倦乏力、骨髓抑制、肝肾功能损伤等不良反应发生率比较差异无统计学意义(P>0.05)。结论晚期非小细胞肺癌脑转移治疗中联用小分子TKI吉非替尼、同期放疗可增强近期疗效,改善患者生活质量,且不良反应少。Objective To investigate the short-term efficacy of tyrosine kinase inhibitor(TKI)combined with concurrent radiotherapy in the treatment of patients with advanced non-small cell lung cancer with brain metastasis.Methods The clinical data of 71 patients with advanced non-small cell lung cancer with brain metastasis in our hospital from January 2017 to January 2019 were retrospectively analyzed.According to the treatment methods,34 patients treated with whole brain radiotherapy were selected as control group,and 37 patients treated with small-molecule TKI combined with concurrent radiotherapy were selected as study group.Short-term effects,Quality of life(QOL)and adverse reactions were compared between the two groups.Results After treatment,the control rate of brain metastasis in study group(72.94%)was higher than that in control group(47.06%)(P<0.05);the QOL score of study group was higher than that of control group(P<0.05);there was no significant difference in the incidence of adverse reactions(including nausea,vomiting,diarrhea,rash,f atigue,bone marrow suppression,liver and kidney function injury)between the two groups(P>0.05).Conclusion The combination of small-molecule TKI gefitinib with concurrent radiotherapy in the treatment of brain metastasis of advanced non-small cell lung cancer can enhance the short-term efficacy and improve the quality of life of patients with fewer adverse reactions.

关 键 词：非小细胞肺癌 脑转移 小分子TKI 吉非替尼 全脑放疗 

分 类 号：R73[医药卫生—肿瘤]